Nitromed — Merger or Acquisition (November 2008)
16 slides from Nitromed's merger presentation, Nov 18, 2008
Slide 1: Archemix / NitroMed Webcast Presentation November 18, 2008
Archemix / NitroMed Webcast Presentation November 18, 2008
Slide 2: Forward-looking statements
Statements in this press release regarding the proposed transaction between NitroMed and Archemix; the expected timetable for completing thetransaction; the combined company’s cash; NitroMed’s plans to achieve compliance with NASDAQ’s listing requirements by means of a reverse stock split; the poten
Slide 3: Forward-looking statements risk factors
There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the risk that NitroMed is unable to complete the sale of its BiDil drug business, which is a condition to the closing of the merg
Slide 4: Archemix / NitroMed Webcast Presentation November 18, 2008
Archemix / NitroMed Webcast Presentation November 18, 2008
Slide 5: The Boards of Archemix and NitroMed have approved a merger
The Boards of Archemix and NitroMed have approved a merger of the two companies NitroMed undertook a thorough evaluation of the alternatives and believes a combination with Archemix provides the best opportunity to build shareholder value NitroMed previously announced it’s divesting substantially al
Slide 6: Combined company will be well-capitalized at closing
Combined company will be well-capitalized with estimated cash/cash equivalents of ~$50-60MM at closing Pro forma ownership of combined company will be split approximately 70% / 30% between Archemix and NitroMed shareholders combined, respectively, subject to adjustment for net cash Pro forma company
Slide 7: Archemix — a Differentiated Company with Diversified Assets and a Balanced Business Model
Archemix — a Differentiated Company with DiversifiedAssetsand aBalanced Business Model
Slide 8: Aptamer Structure and Function
Aptamer Structure and Function Aptamers: Oligonucleotides that bind to protein with high affinity and specificity Aptamers combine many of the advantages of oligonucleotides and biologics – “Chemical Antibodies” ·
Slide 9: Balanced Business Strategy
Balanced Business Strategy Internal Focus: Hematology Other indications · Numerous “aptamer friendly” targets · Direct access to target (IV/SC) · Early proof of concept Oncology • Few or no approved therapies · High unmet medical need · Rapid regulatory path · Less commercialization infrastructure S
Slide 10: Robust Clinical Pipeline
Robust Clinical Pipeline Product Candidate / Indication Research/Preclinical Phase 1 Phase 2 Orphan Hematology ARC1779 Thrombotic Microangiopathies (TMA) ARC1779 Carotid Endarterectomy (CEA) ARC5692 Si c kl e C e ll Di sease Multiple Targets Hemophilia Cardiovascular REG1 Percutaneous Coronary Inter
Slide 11: Strategic partnerships with key rights retained
“Strategic partnerships with key rights retained” Collaborator Deal Economics $240M potential deal value $6M upfront 2008 Option to develop targets $125M potential deal value $3M upfront No encumbered indications/ $260M potential deal value therapeutic areas $6M upfront 2007 Multiple co- $611M poten
Slide 12: Strong Financial History
Strong Financial History Ending year cash balance ($MM) $60 $56 $50 · Merck KGaA · Merck Serono · Takeda $42 $40 · Other BD $42 $36 $30 Series B · Nuvelo Financing · Pfizer · Other BD $20 $17 $10 Series A Financing $3 $0 2002 2003 2004 2005 2006 2007
Slide 13: Leadership Team with Proven Track Record
Larcher} Leadership Team with Proven Track Record Ken Bate President & CEO NitroMed; Millennium; Biogen Duncan Higgons EVP, Business Operations Transform; Alkermes; Lilly Gregg Beloff vp, CFO ImmunoGen; Adams, Harkness & Hil Page Bouchard, DVM ‘SVP, Research & Preclin. Dev. Millenniurn; Wyeth Gilber
Slide 14: Archemix - a Differentiated Company with Diversified Assets and a Balanced Business Model
Archemix Archemix - a Differentiated Company with Diversified Assets and a Balanced Business Model Fou ne srepteetmes | | rumemsp an 1 Team mock reed | a 1s larg we Yast ruc Nec Sn sine aw wae) + Cah fom in past 24 foes nae ‘sanpaeae adhenepe esate {58m enh parterstips with ey gh retained
Slide 15: The Aptamer Therapeutics Company
‘The Aptamer Therapeutics Company Archers Archemix / NitroMed Webcast Presentation November 18, 2008 QMyitaomen
Slide 16: Inomnecion wt he ep rr, in wl le wth ne EC eptatn pen frm
Inomnecion wt he ep rr, in wl le wth ne EC eptatn pen frm 4 SRO ein pany Steeles te ot ey See/osioca wa fe a ay rhe pete Rite reer sale of the eto ae ee eae nganaratmomngne es Se ka eae an cea meee eksvoltatemcnbentsnl sve tense i nes ect i nope Poerenes is ie ereeaced TF fet, conacheg Wee re vere,